Management of the older person with atrial fibrillation

被引:34
作者
Aronow, WS
机构
[1] New York Med Coll, Div Cardiol, Dept Med, New Rochelle, NY 10804 USA
[2] New York Med Coll, Div Geriatr, Westchester Med Ctr, New Rochelle, NY 10804 USA
来源
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES | 2002年 / 57卷 / 06期
关键词
D O I
10.1093/gerona/57.6.M352
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to slow immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and with symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds that are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and should be continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in older persons, ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiarrhythmic drugs. Digoxin should not be used to treat patients with paroxysmal AF. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should receive 325 mg of aspirin daily.
引用
收藏
页码:M352 / M363
页数:12
相关论文
共 134 条
[1]   EFFICACY AND SAFETY OF ESMOLOL VS PROPRANOLOL IN THE TREATMENT OF SUPRAVENTRICULAR TACHYARRHYTHMIAS - A MULTICENTER DOUBLE-BLIND CLINICAL-TRIAL [J].
ABRAMS, J ;
ALLEN, J ;
ALLIN, D ;
ANDERSON, J ;
ANDERSON, S ;
BLANSKI, L ;
CHADDA, K ;
DIBIANCO, R ;
FAVROT, L ;
GONZALEZ, J ;
HOROWITZ, L ;
LADDU, A ;
LEE, R ;
MACCOSBE, P ;
MORGANROTH, J ;
NARULA, O ;
SINGH, B ;
SINGH, J ;
STECK, J ;
SWERDLOW, C ;
TURLAPATY, P ;
WALDO, A .
AMERICAN HEART JOURNAL, 1985, 110 (05) :913-922
[2]   Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial [J].
Al-Khatib, SM ;
Pieper, KS ;
Lee, KL ;
Mahaffey, KW ;
Hochman, JS ;
Pepine, CJ ;
Kopecky, SL ;
Akkerhuis, M ;
Stepinska, J ;
Simoons, ML ;
Topol, EJ ;
Califf, RM ;
Harrington, RA .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (01) :76-79
[3]  
Allessie MA, 2001, CIRCULATION, V103, P769
[4]   PROSPECTIVE RANDOMIZED TRIAL OF ATRIAL VERSUS VENTRICULAR PACING IN SICK-SINUS SYNDROME [J].
ANDERSEN, HR ;
THUESEN, L ;
BAGGER, JP ;
VESTERLUND, T ;
THOMSEN, PEB .
LANCET, 1994, 344 (8936) :1523-1528
[5]   PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK [J].
ANDERSON, DC ;
ASINGER, RW ;
NEWBURG, SM ;
FARMER, CC ;
WANG, K ;
BUNDLIE, SR ;
KOLLER, RL ;
JAGIELLA, WM ;
KREHER, S ;
JORGENSEN, CR ;
SHARKEY, SW ;
FLAKER, GC ;
WEBEL, R ;
NOLTE, B ;
STEVENSON, P ;
BYER, J ;
WRIGHT, W ;
CHESEBRO, JH ;
WIEBERS, DO ;
HOLLAND, AE ;
MILLER, DM ;
BARDSLEY, WT ;
LITIN, SC ;
MEISSNER, I ;
ZERBE, DM ;
MCANULTY, JH ;
MARCHANT, C ;
COULL, BM ;
FELDMAN, G ;
HAYWARD, A ;
GANDARA, E ;
MACMILLAN, K ;
BLANK, N ;
LEONARD, AD ;
KANTER, MC ;
ISENSEE, LM ;
QUIROGA, ES ;
PRESTI, CH ;
TEGELER, CH ;
LOGAN, WR ;
HAMILTON, WP ;
GREEN, BJ ;
BACON, RS ;
REDD, RM ;
CADELL, DJ ;
GOMEZ, CR ;
JANOSIK, DL ;
LABOVITZ, AJ ;
KELLEY, RE ;
CHAHINE, R .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :1-5
[6]  
Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273
[7]  
ANDERSON DC, 1992, ANN INTERN MED, V116, P6
[8]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[9]  
ARONOW W S, 1991, Drugs and Aging, V1, P98, DOI 10.2165/00002512-199101020-00002
[10]  
Aronow W S, 2000, Heart Dis, V2, P151